The Top 5 Biosimilars Articles for the Week of July 29
The Center for Biosimilars® recaps the top stories for the week of July 29, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 29, 2019.
Number 5: A proposed amendment to the Biologics Price Competition and Innovation Act would require that the FDA continue to review insulins submitted as drugs even after the March 2020 transition of insulins to regulation as biologics.
Number 4: Amgen lost its fight to block Coherus BioSciences from selling its biosimilar pegfilgrastim.
Number 3: In the United States, Humira sales grew by $3.8 billion last quarter, up 7.7% from the prior year.
Number 2: Pfizer’s off-patent drug unit, Upjohn, and Mylan have announced a deal under which they will combine to form a new company that will have expanded reach.
Number 1: The Federal Trade Commission issued civil subpoenas to Johnson & Johnson as part of an antitrust investigation into its strategy to defend sales of its innovator infliximab against biosimilar competition.
Finally, last week, our e-newsletter asked whether you think that the price discounts offered on Amgen’s 2 newly launched anticancer biosimilars are enough to spur US uptake.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
